A Glimpse Into The Expert Outlook On GE HealthCare Techs Through 10 Analysts

Ratings for GE HealthCare Techs (NASDAQ:GEHC) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	4	2	4	0	0
Last 30D	1	0	0	0	0
1M Ago	1	0	2	0	0
2M Ago	1	0	0	0	0
3M Ago	1	2	2	0	0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $90.1, with a high estimate of $105.00 and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 4.63% increase from the previous average price target of $86.11.

Diving into Analyst Ratings: An In-Depth Exploration

An in-depth analysis of recent analyst actions unveils how financial experts perceive GE HealthCare Techs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Rick Wise	Stifel	Raises	Buy	$95.00	$90.00
Craig Bijou	B of A Securities	Raises	Neutral	$92.00	$82.00
Joanne Wuensch	Citigroup	Raises	Neutral	$88.00	$83.00
Matthew Taylor	Jefferies	Raises	Buy	$105.00	$95.00
Ryan Zimmerman	BTIG	Maintains	Buy	$87.00	$87.00
Patrick Wood	Morgan Stanley	Raises	Equal-Weight	$80.00	$74.00
Vijay Kumar	Evercore ISI Group	Raises	Outperform	$92.00	$88.00
Larry Biegelsen	Wells Fargo	Lowers	Overweight	$87.00	$89.00
Ryan Zimmerman	BTIG	Raises	Buy	$89.00	$87.00
Matt Miksic	Barclays	Announces	Equal-Weight	$86.00	-

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to GE HealthCare Techs. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of GE HealthCare Techs compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of GE HealthCare Techs's stock. This examination reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GE HealthCare Techs's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on GE HealthCare Techs analyst ratings.

Discovering GE HealthCare Techs: A Closer Look

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Understanding the Numbers: GE HealthCare Techs's Finances

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Over the 3M period, GE HealthCare Techs showcased positive performance, achieving a revenue growth rate of 5.78% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: GE HealthCare Techs's net margin excels beyond industry benchmarks, reaching 8.67%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): GE HealthCare Techs's ROE excels beyond industry benchmarks, reaching 4.53%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): GE HealthCare Techs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.25%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: GE HealthCare Techs's debt-to-equity ratio stands notably higher than the industry average, reaching 1.08. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

The Core of Analyst Ratings: What Every Investor Should Know

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.